PARIS, FRANCE, 24 April 2024 - Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.       Q1 2024   Q1 2023   % change   €m   €m   Actual CER1 Growth platforms2 509.7 452.0 12.8% 16.2% New medicines3 45.5 14.3 n/a n/a Somatuline® 257.8 263.2 -2.0% -1.3% Other 9.5 12.4 -23.8% -20.5% Total Sales 822.4 741.9 10.9% 13.3% Highlights Total-sales growth of 13.3% at CER1, or 10.9% as reported, driven by the 16.2%1 increase in sales of the growth platforms2 and the increased contributions from new medicines, while Somatuline sales declined by only 1.3%1 Regulatory approval and launch of Onivyde in the U.S. as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC) Confirmation of financial guidance for 2024 "An excellent first-quarter performance has laid a solid foundation for Ipsen's growth in 2024", commented David Loew, Chief Executive Officer, Ipsen. "The delivery of our strategic plan continues to be evidenced by a strong top line, supported by the success of the growth platforms and the increased contribution of the new medicines. Moreover, the pipeline continues to deliver, illustrated this quarter by the regulatory approval in the U.S. of Onivyde as a first-line treatment for pancreatic cancer. "This year marks a pivotal period for ...